Article | Published:

The inducible kinase IKKi is required for IL-17-dependent signaling associated with neutrophilia and pulmonary inflammation

Nature Immunology volume 12, pages 844852 (2011) | Download Citation

This article has been updated

Abstract

Interleukin 17 (IL-17) is critical in the pathogenesis of inflammatory and autoimmune diseases. Here we report that Act1, the key adaptor for the IL-17 receptor (IL-7R), formed a complex with the inducible kinase IKKi after stimulation with IL-17. Through the use of IKKi-deficient mice, we found that IKKi was required for IL-17-induced expression of genes encoding inflammatory molecules in primary airway epithelial cells, neutrophilia and pulmonary inflammation. IKKi deficiency abolished IL-17-induced formation of the complex of Act1 and the adaptors TRAF2 and TRAF5, activation of mitogen-activated protein kinases (MAPKs) and mRNA stability, whereas the Act1–TRAF6–transcription factor NF-κB axis was retained. IKKi was required for IL-17-induced phosphorylation of Act1 on Ser311, adjacent to a putative TRAF-binding motif. Substitution of the serine at position 311 with alanine impaired the IL-17-mediated Act1-TRAF2-TRAF5 interaction and gene expression. Thus, IKKi is a kinase newly identified as modulating IL-17 signaling through its effect on Act1 phosphorylation and consequent function.

Access optionsAccess options

Rent or Buy article

Get time limited or full article access on ReadCube.

from$8.99

All prices are NET prices.

Change history

  • 22 August 2011

    In the version of this article initially published, the author Mark R. Chance was incorrectly identified as Mark Chance. The error has been corrected in the HTML and PDF versions of the article.

Accessions

References

  1. 1.

    et al. Reciprocal developmental pathways for the generation of pathogenic effector TH17 and regulatory T cells. Nature 441, 235–238 (2006).

  2. 2.

    et al. IL-17 is essential for host defense against cutaneous Staphylococcus aureus infection in mice. J. Clin. Invest. 120, 1762–1773 (2010).

  3. 3.

    et al. Th17 cells and IL-17 receptor signaling are essential for mucosal host defense against oral candidiasis. J. Exp. Med. 206, 299–311 (2009).

  4. 4.

    et al. Interleukin 17-producing CD4+ effector T cells develop via a lineage distinct from the T helper type 1 and 2 lineages. Nat. Immunol. 6, 1123–1132 (2005).

  5. 5.

    & The IL-23/IL-17 axis in inflammation. J. Clin. Invest. 116, 1218–1222 (2006).

  6. 6.

    & Interleukin-17 family members and inflammation. Immunity 21, 467–476 (2004).

  7. 7.

    et al. IL-23 drives a pathogenic T cell population that induces autoimmune inflammation. J. Exp. Med. 201, 233–240 (2005).

  8. 8.

    et al. A distinct lineage of CD4 T cells regulates tissue inflammation by producing interleukin 17. Nat. Immunol. 6, 1133–1141 (2005).

  9. 9.

    , & TH17 cells in asthma and COPD. Annu. Rev. Physiol. 72, 495–516 (2010).

  10. 10.

    & The role of Th17 cytokines in primary mucosal immunity. Cytokine Growth Factor Rev. 21, 443–448 (2010).

  11. 11.

    Th17 cells in mucosal immunity and tissue inflammation. Semin. Immunopathol. 32, 1–2 (2010).

  12. 12.

    et al. Antigen-specific T cell sensitization is impaired in IL-17-deficient mice, causing suppression of allergic cellular and humoral responses. Immunity 17, 375–387 (2002).

  13. 13.

    , & Act1 adaptor protein is an immediate and essential signaling component of interleukin-17 receptor. J. Biol. Chem. 281, 35603–35607 (2006).

  14. 14.

    , , , & IL-17 enhances chemokine gene expression through mRNA stabilization. J. Immunol. 179, 4135–4141 (2007).

  15. 15.

    & IL-17RC: a partner in IL-17 signaling and beyond. Semin. Immunopathol. 32, 33–42 (2010).

  16. 16.

    et al. Requirement for both JAK-mediated PI3K signaling and ACT1/TRAF6/TAK1-dependent NF-κB activation by IL-17A in enhancing cytokine expression in human airway epithelial cells. J. Immunol. 179, 6504–6513 (2007).

  17. 17.

    et al. Up-regulation of CC chemokine ligand 20 expression in human airway epithelium by IL-17 through a JAK-independent but MEK/NF-kappaB-dependent signaling pathway. J. Immunol. 175, 6676–6685 (2005).

  18. 18.

    et al. The adaptor Act1 is required for interleukin 17-dependent signaling associated with autoimmune and inflammatory disease. Nat. Immunol. 8, 247–256 (2007).

  19. 19.

    et al. IL-17 receptor signaling inhibits C/EBPβ by sequential phosphorylation of the regulatory 2 domain. Sci. Signal. 2, ra8 (2009).

  20. 20.

    & Structure-function relationships in the IL-17 receptor: implications for signal transduction and therapy. Cytokine 41, 92–104 (2008).

  21. 21.

    et al. Cutting edge: interleukin 17 signals through a heteromeric receptor complex. J. Immunol. 177, 36–39 (2006).

  22. 22.

    , , , & The STIR-domain superfamily in signal transduction, development and immunity. Trends Biochem. Sci. 28, 226–229 (2003).

  23. 23.

    et al. The critical role of epithelial-derived Act1 in IL-17- and IL-25-mediated pulmonary inflammation. J. Immunol. 182, 1631–1640 (2009).

  24. 24.

    et al. Act1, an NF-κB-activating protein. Proc. Natl. Acad. Sci. USA 97, 10489–10493 (2000).

  25. 25.

    , & Requirement of tumor necrosis factor receptor-associated factor (TRAF)6 in interleukin 17 signal transduction. J. Exp. Med. 191, 1233–1240 (2000).

  26. 26.

    et al. Act1, a U-box E3 ubiquitin ligase for IL-17 signaling. Sci. Signal. 2, ra63 (2009).

  27. 27.

    , & IKKepsilon is part of a novel PMA-inducible IκB kinase complex. Mol. Cell 5, 513–522 (2000).

  28. 28.

    et al. IKK-i, a novel lipopolysaccharide-inducible kinase that is related to IkappaB kinases. Int. Immunol. 11, 1357–1362 (1999).

  29. 29.

    et al. IKKɛ and TBK1 are essential components of the IRF3 signaling pathway. Nat. Immunol. 4, 491–496 (2003).

  30. 30.

    et al. The roles of two IκB kinase-related kinases in lipopolysaccharide and double stranded RNA signaling and viral infection. J. Exp. Med. 199, 1641–1650 (2004).

  31. 31.

    et al. IPS-1, an adaptor triggering RIG-I- and Mda5-mediated type I interferon induction. Nat. Immunol. 6, 981–988 (2005).

  32. 32.

    et al. Triggering the interferon antiviral response through an IKK-related pathway. Science 300, 1148–1151 (2003).

  33. 33.

    et al. Interleukin-1-mediated stabilization of mouse KC mRNA depends on sequences in both 5′- and 3′-untranslated regions. J. Biol. Chem. 275, 12987–12993 (2000).

  34. 34.

    , , , & Structural basis for self-association and receptor recognition of human TRAF2. Nature 398, 533–538 (1999).

  35. 35.

    , , , & The structural basis for the recognition of diverse receptor sequences by TRAF2. Mol. Cell 4, 321–330 (1999).

  36. 36.

    et al. Distinct molecular mechanism for initiating TRAF6 signalling. Nature 418, 443–447 (2002).

  37. 37.

    et al. IL-17 regulates CXCL1 mRNA stability via an AUUUA/tristetraprolin-independent sequence. J. Immunol. 184, 1484–1491 (2010).

  38. 38.

    , & Interleukin 1alpha-induced NFκB activation and chemokine mRNA stabilization diverge at IRAK1. J. Biol. Chem. 283, 15689–15693 (2008).

  39. 39.

    et al. Treatment with IL-17 prolongs the half-life of chemokine CXCL1 mRNA via the TRAF5 and the splicing regulatory factor SF2/ASF. Nat. Immunol. advance online publication, doi:10.1038/ni.2081 (7 Aug 2011).

  40. 40.

    & MNK1, a new MAP kinase-activated protein kinase, isolated by a novel expression screening method for identifying protein kinase substrates. EMBO J. 16, 1921–1933 (1997).

  41. 41.

    et al. Mitogen-activated protein kinase-activated protein kinase 2 regulates tumor necrosis factor mRNA stability and translation mainly by altering tristetraprolin expression, stability, and binding to adenine/uridine-rich element. Mol. Cell. Biol. 26, 2399–2407 (2006).

  42. 42.

    et al. MNK kinases regulate multiple TLR pathways and innate proinflammatory cytokines in macrophages. Am. J. Physiol. Gastrointest. Liver Physiol. 294, G452–G459 (2008).

  43. 43.

    , , , & Mnk2 and Mnk1 are essential for constitutive and inducible phosphorylation of eukaryotic initiation factor 4E but not for cell growth or development. Mol. Cell. Biol. 24, 6539–6549 (2004).

  44. 44.

    et al. IL-17-induced NF-κB activation via CIKS/Act1: physiologic significance and signaling mechanisms. J. Biol. Chem. 286, 12881–12890 (2011).

  45. 45.

    et al. Differentiated murine airway epithelial cells synthesize a leukocyte-adhesive hyaluronan matrix in response to endoplasmic reticulum stress. J. Biol. Chem. 283, 26283–26296 (2008).

  46. 46.

    , , & The Xplor-NIH NMR molecular structure determination package. J. Magn. Reson. 160, 65–73 (2003).

  47. 47.

    , , , & The SWISS-MODEL Repository and associated resources. Nucleic Acids Res. 37, D387–D392 (2009).

  48. 48.

    & The SWISS-MODEL Repository of annotated three-dimensional protein structure homology models. Nucleic Acids Res. 32, D230–D234 (2004).

  49. 49.

    & Docking of protein-protein complexes on the basis of highly ambiguous intermolecular distance restraints derived from 1H/15N chemical shift mapping and backbone 15N–1H residual dipolar couplings using conjoined rigid body/torsion angle dynamics. J. Am. Chem. Soc. 125, 2902–2912 (2003).

  50. 50.

    & Chi1 rotamer populations and angles of mobile surface side chains are accurately predicted by a torsion angle database potential of mean force. J. Am. Chem. Soc. 124, 2866–2867 (2002)

Download references

Acknowledgements

We thank T. Maniatis (Harvard University) for IKKi-deficient and wild-type C57BL/6 control mice; and the High Performance Computing Resource in the Core Facility for Advanced Research Computing and Center of Proteomics and Bioinformatics at Case Western Reserve University. Supported by the American Asthma Foundation (X.L.), the US National Institutes of Health (R01HL098935-01A1 to X.L.) and the American Heart Association (09POST2010041 to R.C.P.).

Author information

Author notes

    • Katarzyna Bulek
    •  & Caini Liu

    These authors contributed equally to this work.

Affiliations

  1. Department of Immunology, Lerner Research Institute, Cleveland Clinic Foundation, Cleveland, Ohio, USA.

    • Katarzyna Bulek
    • , Caini Liu
    • , Shadi Swaidani
    • , Muhammet F Gulen
    • , Tomasz Herjan
    • , Amina Abbadi
    • , Wen Qian
    • , Dongxu Sun
    • , Thomas Hamilton
    •  & Xiaoxia Li
  2. Center for Proteomics & Bioinformatics, School of Medicine, Case Western Reserve University, Cleveland, Ohio, USA.

    • Liwen Wang
    •  & Mark R Chance
  3. Department of Molecular Cardiology, Lerner Research Institute, Cleveland Clinic Foundation, Cleveland, Ohio, USA.

    • Richard C Page
    •  & Saurav Misra
  4. Department of Biomedical Engineering, Lerner Research Institute, Cleveland Clinic Foundation, Cleveland, Ohio, USA.

    • Mark Lauer
    •  & Vincent Hascall
  5. Department of Pathobiology, Lerner Research Institute, Cleveland Clinic Foundation, Cleveland, Ohio, USA.

    • Mark Aronica

Authors

  1. Search for Katarzyna Bulek in:

  2. Search for Caini Liu in:

  3. Search for Shadi Swaidani in:

  4. Search for Liwen Wang in:

  5. Search for Richard C Page in:

  6. Search for Muhammet F Gulen in:

  7. Search for Tomasz Herjan in:

  8. Search for Amina Abbadi in:

  9. Search for Wen Qian in:

  10. Search for Dongxu Sun in:

  11. Search for Mark Lauer in:

  12. Search for Vincent Hascall in:

  13. Search for Saurav Misra in:

  14. Search for Mark R Chance in:

  15. Search for Mark Aronica in:

  16. Search for Thomas Hamilton in:

  17. Search for Xiaoxia Li in:

Contributions

K.B., C.L., S.S., L.W., M.F.G., T.H., W.Q. and D.S., experiments; K.B. and C.L., experimental design, performance and interpretation and writing of the manuscript; L.W. and M.R.C., mass spectrometry study; R.C.P. and S.M., structure modeling; A.A., M.L. and V.H., assistance with the primary mouse airway epithelial cell culture; M.A., assistance with in vivo experiments; X.L. and T.H., design and interpretation of experiments and writing of the manuscript; all authors, review of the final manuscript.

Competing interests

The authors declare no competing financial interests.

Corresponding author

Correspondence to Xiaoxia Li.

About this article

Publication history

Received

Accepted

Published

DOI

https://doi.org/10.1038/ni.2080

Further reading